Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $12.50 target price on the stock. HC Wainwright’s target price indicates a potential upside of 90.55% from the company’s current price.

Several other brokerages also recently weighed in on TRVI. Needham & Company LLC lowered their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $9.00 to $29.00 in a report on Monday, March 10th. Finally, Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Trevi Therapeutics has an average rating of “Buy” and a consensus target price of $15.81.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $6.56 on Wednesday. The firm has a market cap of $504.24 million, a PE ratio of -14.91 and a beta of 0.90. The firm’s 50 day simple moving average is $4.44 and its 200-day simple moving average is $3.68. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. Equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. This trade represents a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 24.37% of the company’s stock.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds have recently made changes to their positions in TRVI. Summit Investment Advisors Inc. lifted its holdings in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at $49,000. Squarepoint Ops LLC purchased a new position in Trevi Therapeutics during the 4th quarter worth $58,000. Finally, Intech Investment Management LLC purchased a new position in Trevi Therapeutics during the 3rd quarter worth $63,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.